Loading clinical trials...
Loading clinical trials...
An Open-Label, Single-Arm, Multicenter Phase 1 Study Evaluating the Safety and Pharmacokinetics of Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
Conditions
Interventions
duvelisib
Locations
3
Japan
Site Reference ID/Investigator# 141826
Aichi, Japan
Site Reference ID/Investigator# 141595
Fukuoka, Japan
Site Reference ID/Investigator# 141594
Tokyo, Japan
Start Date
November 1, 2015
Primary Completion Date
December 1, 2016
Completion Date
February 1, 2017
Last Updated
February 6, 2017
NCT05139017
NCT06337318
NCT05529069
NCT07388563
NCT06263491
NCT07350863
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions